Results 11 to 20 of about 369,580 (326)

Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins

Blood Cancer Discovery, 2021
Abstract The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations.
Yasen Maimaitiyiming, Qian Qian Wang, Chang Yang, Yasumitsu Ogra, Yinjun Lou, Clayton A. Smith, Liaqat Hussain, Yi Ming Shao, Jiebo Lin, Jinfeng Liu, Lingfang Wang, Yong Zhu, Haiyan Lou, Yuan Huang, Xiaoxia Li, Kao-Jung Chang, Hao Chen, Hongyan Li, Ying Huang, Eric Tse, Jie Sun, Na Bu, Shih-Hwa Chiou, Yan Fang Zhang, Hao Ying Hua, Li Ya Ma, Ping Huang, Ming Hua Ge, Feng-Lin Cao, Xiaodong Cheng, Hongzhe Sun, Jin Zhou, Vasilis Vasliou, Pengfei Xu, Jie Jin, Mikael Bjorklund, Hong-Hu Zhu, Chih-Hung Hsu, Hua Naranmandura   +38 more
openaire   +2 more sources

Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. [PDF]

Blood, 1995
Many human leukemias are characterized by chromosomal translocations yielding hybrid RNAs capable of encoding fusion chimeric proteins. The unique amino acid sequences found in these oncogenic fusion proteins represent true tumor-specific antigens that are potentially immunogenic.
Monica Bocchia, Peggy, Wentworth, S. Southwood, John Sidney, Kimberly J. McGraw, D. Scheinberg, Alessandro Sette   +7 more
semanticscholar   +5 more sources

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

International Journal of Molecular Sciences, 2023
CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 is emerging as a commonly detected fusion partner in multiple oncogenic fusion proteins.
Jasmine Vargas, Georgios Pantouris
openaire   +2 more sources

The fusion partner specifies the oncogenic potential of NUP98 fusion proteins [PDF]

Leukemia Research, 2013
NUP98 is among the most promiscuously translocated genes in hematological diseases. Among the 28 known fusion partners, there are two categories: homeobox genes and non-homeobox genes. The homeobox fusion partners are well-studied in animal models, resulting in HoxA cluster overexpression and hematological disease.
Saw, J, Curtis, DJ, Hussey, DJ, Dobrovic, A, Aplan, PD, Slape, CI   +5 more
openaire   +3 more sources

Oncogenic All1 fusion proteins target Drosha-mediated microRNA processing [PDF]

Proceedings of the National Academy of Sciences, 2007
MicroRNAs (miRNAs) are noncoding small RNA of ≈22 bases, which suppress expression of target genes through translational block or degradation of a target's transcript. Recent studies uncovered specific miRNA expression profiles in human malignancies.
Tatsuya Nakamura, Eli Canaani, CROCE, Carlo Maria   +2 more
openaire   +3 more sources

One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma

Journal of Bone Oncology, 2021
EWS/FLI is the defining mutation of Ewing sarcoma. This oncogene drives malignant transformation and progression and occurs in a genetic background characterized by few other recurrent cooperating mutations. In addition, the tumor is absolutely dependent
Guillermo Flores, Patrick J. Grohar
doaj   +1 more source

Mutation Profile of Well-Differentiated Thyroid Cancer in Asians [PDF]

Endocrinology and Metabolism, 2015
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase ...
Young Shin Song, Jung Ah Lim, Young Joo Park   +2 more
doaj   +1 more source

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins [PDF]

Proceedings of the National Academy of Sciences, 2013
Significance ROS1 fusion kinases are critical oncogenes in several malignancies, suggesting that ROS1 inhibitors are likely to be effective molecularly targeted therapies in these patients. Although phase I/II clinical trials using the ALK/ROS1 inhibitor crizotinib to treat ROS1 fusion-harboring non–small-cell lung cancer ...
Monika A, Davare, Anna, Saborowski, Christopher A, Eide, Cristina, Tognon, Rebecca L, Smith, Johannes, Elferich, Anupriya, Agarwal, Jeffrey W, Tyner, Ujwal P, Shinde, Scott W, Lowe, Brian J, Druker   +10 more
openaire   +2 more sources

The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. [PDF]

, 2012
The PICALM (CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the
Anastasi, J, Brodsky, FM, Fernald, AA, Le Beau, MM, Stoddart, A, Tennant, TR   +5 more
core   +2 more sources

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

Oncogene, 2016
The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment.
C. Daly, Carla Castanaro, Wen Zhang, Q. Zhang, Yi Wei, M. Ni, T. Young, L. Zhang, E. Burova, G. Thurston   +9 more
semanticscholar   +1 more source